Skip to content

IPF Evaluation: Discussing the way forward

A major outcome of the British Pharmacological Society’s ‘Focus on Pharmacology’ project has been a 2016 review of the Integrative Pharmacology Fund (IPF), a shared venture with AstraZeneca, GlaxoSmithKline, Pfizer, public funders and the Society to help support in vivo knowledge and skills. The impact of the £22m fund over its 12-year lifetime was evaluated and recommendations made for in vivo education, research and training. Drawing upon expertise from across the in vivo community, the Society and The Physiological Society co-hosted a workshop in November 2017 to discuss how these recommendations might be implemented. Future challenges arising from a changing scientific landscape were discussed as well as how best to nurture networks of good practice. Going forward, we will condense the outputs of these discussions and produce a report that will inform the necessary next steps for the in vivo community to ensure a sustainable and well-rounded future in vivo landscape.

Latest news & activity

Press releases

Following on from its recent publication of the 2025 Annual Review, the British Pharmacological Society has launched its new BPS Strategy 2026 - 2030:…

Annual Review

We’re pleased to share our 2025 Annual Review, which is now live!

The Annual Review captures a year of progress and purpose across the British…

Event announcement

 

The wait is over... Pharmacology 2026 is now open for registration! See below to find out how to get the best value for money, how to share your…